Clinical Outcomes in Patients Undergoing Percutaneous Closure of Periprosthetic Paravalvular Leaks  by Ruiz, Carlos E. et al.
Journal of the American College of Cardiology Vol. 58, No. 21, 2011
© 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00FOCUS ISSUE: STRUCTURAL HEART DISEASE
Clinical Research
Clinical Outcomes in Patients Undergoing
Percutaneous Closure of Periprosthetic Paravalvular Leaks
Carlos E. Ruiz, MD, PHD, Vladimir Jelnin, MD, Itzhak Kronzon, MD, Yuriy Dudiy, MD,
Raquel Del Valle-Fernandez, MD, Bryce N. Einhorn, Paul T. L. Chiam, MD, Claudia Martinez, MD,
Rocio Eiros, MS, Gary Roubin, MD, PHD, Howard A. Cohen, MD
New York, New York
Objectives The purpose of this study was to evaluate the feasibility and efficacy of the percutaneous device closure of a
consecutive series of patients with periprosthetic paravalvular leaks referred to our structural heart disease cen-
ter with congestive heart failure and hemolytic anemia.
Background Clinically significant periprosthetic paravalvular leak is an uncommon but serious complication after surgical
valve replacement. Percutaneous closure has been utilized as an alternative to surgical repair of this defect in
high-risk surgical patients.
Methods This is a retrospective review of 57 percutaneous paravalvular leak closures that were performed in 43 patients
(67% male, mean age 69.4  11.7 years) between April 2006 and September 2010. Integrated imaging modal-
ities were used for the evaluation, planning, and guidance of the interventions.
Results Closure was successful in 86% of leaks and in 86% of patients. Twenty-eight of 35 patients improved by at least
1 New York Heart Association functional class. The percentage of patients requiring blood transfusions and/or
erythropoietin injections post-procedure decreased from 56% to 5%. Clinical success was achieved in 89% of the
patients in whom procedure was successful. The survival rates for patients at 6, 12, and 18 months after para-
valvular leak closures were 91.9%, 89.2%, and 86.5%, respectively. Freedom from cardiac-related death at
42 months post-procedure was 91.9%.
Conclusions Percutaneous closure of symptomatic paravalvular leaks, facilitated by integrated imaging modalities has a high
rate of acute and long-term success and appears to be effective in managing symptoms of heart failure and he-
molytic anemia. (J Am Coll Cardiol 2011;58:2210–7) © 2011 by the American College of Cardiology
Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.03.074Paravalvular leak is a common complication after surgical
valve replacement, with reported incidences at a follow-up
of 2% to 10% for prosthetic valves in the aortic position
(1,2) and 7% to 17% for prosthetic valves in the mitral
position (1–3). Most paravalvular leaks remain clinically
silent; however, 1% to 3% of patients with paravalvular leak
require reoperations due to symptomatic paravalvular leak
(4–6). Paravalvular leaks manifest with symptoms of con-
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2011, accepted March 10, 2011.gestive heart failure (CHF), hemolysis, or in most cases, the
combination of both.
Surgical closure of paravalvular leaks remains the most
common therapy for these defects; however, re-do surgery
has some limitations, depending on the number of patient
comorbidities, including a high recurrence rate (7) as well as
high morbidity and mortality rates (7–9). Furthermore,
mortality increases progressively with the number of reop-
erations: 13% after the first, 15% after the second, and 37%
after the third (9).
Since first reported by Hourihan et al. (10) in 1992,
percutaneous closure of periprosthetic paravalvular leaks
has been proposed as an attractive alternative to surgical
closure and has been found to alleviate the consequences
and symptoms of paravalvular leaks in high-risk patients
(11). This retrospective study was performed to review
the feasibility and efficacy of the percutaneous device
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vular leaks referred to our Structural Heart Disease
Center.
Methods
Definitions for this study of patients with paravalvular
leaks. Periprosthetic paravalvular leak is defined as a regur-
gitant jet, demonstrated by Doppler echocardiography,
originating between the outer margin of the prosthetic
sewing ring and the native tissues around the valve. Con-
gestive heart failure is defined as symptoms consistent with
a New York Heart Association (NYHA) functional class
greater than II. Symptomatic hemolysis is defined as hemo-
lytic anemia (hemoglobin 10 g/dl, lactate dehydrogenase
600 mg/dl, haptoglobin 10 mg/dl) requiring 2 U of
blood transfusions and/or erythropoietin injections within
90 days to maintain hemoglobin 10 g/dl, without any
other source of blood loss. Anatomic location of the leaks is
based on our own adaptation of the accepted surgical
nomenclature using the clock-face reference (Fig. 1)
(12,13). Technical success is defined as a successful deploy-
ment of an occlusive device across the paravalvular leak
without any mechanical interference with the valve prosthe-
sis, or acute conversion to surgery. Procedural outcome
events are defined as events occurring during the procedure
and within the subsequent 24 h; such events include
procedure-related death, cardiovascular death, neurological
events (i.e., transient ischemic attacks and stroke), myocar-
dial infarction, cardiac tamponade, vascular access site
bleeding requiring intervention and/or blood transfusions,
and urgent conversion to conventional open-chest surgery.
Procedural-related death was defined as any death that was
adjudicated to be a result of an intraprocedural complica-
tion. Thirty-day outcome events, as assessed by telephone or
during a clinic visit, include procedural outcome events and
those occurring within 30 days of the procedure, including
death from all causes, cardiovascular death, myocardial
infarction, and neurological events (i.e., reversible transient
ischemic attacks and irreversible stroke). Clinical success is
defined as an improvement in NYHA functional class of at
least 1 class within a period of 6 months and/or an
improvement in mechanical hemolysis allowing the patient
to become transfusion free.
Patient population. Between April 2006 and September
010, 44 consecutive patients were referred to the Lenox
ill Hospital Structural and Congenital Heart Disease
enter for possible percutaneous paravalvular leak closure.
ne patient was excluded because of the need for open-
eart surgery for additional cardiac pathology. No patient
as excluded on the basis of their risk, and all remaining 43
atients underwent 57 percutaneous paravalvular leaks clo-
ure procedures. Patient demographics and medical history
re shown in Table 1. The group mean age was 69.4  11.7
ears (range 28 to 85 years), and 29 (67%) were male.
wenty-eight patients had 1 prosthetic valve and 15 had 2prosthetic valves, in the mitral
and/or aortic position. The me-
dian time since last valve replace-
ment was 23.5 months and
ranged from 2 to 322 months.
Patients exhibited a multitude
of comorbidities: 36 (84%) had
CHF, 26 (60%) had systemic
hypertension, 18 (42%) had ex-
tensive coronary artery disease,
14 (33%) had pulmonary hyper-
tension, 14 (33%) had a perma-
nent pacemaker, 14 (33%) had
prior cardiac bypass surgery, 14 (33%) had chronic renal
insufficiency, and 10 (23%) had atrial fibrillation. All pa-
tients were symptomatic with severe heart failure and/or
mechanical hemolytic anemia requiring multiple transfu-
sions. Hemolysis alone was the indication for paravalvular
leak closure in 8 (14%) procedures, CHF alone was the
indication in 9 (16%) procedures, and both hemolysis and
CHF were the indications in the other 40 (70%) procedures.
There were no signs of active infection in any patient before
device closure.
Figure 1 Left Atrial Perspective View: Surgical View
The mitral-aortic fibrous continuity corresponds to 12 o’clock in both clocks;
the atrial septum corresponds to 3 o’clock, the posterolateral free wall corre-
sponds to 6 o’clock, and the atrial appendage corresponds to 9 o’clock. For
the aortic valve, the noncoronary cusp is between 7 o’clock and 11 o’clock,
the left coronary cusp is between 11 o’clock and 3 o’clock, and the right coro-
nary cusp is between 3 o’clock and 7 o’clock. Ao  aorta; H  head;
LAA  left atrial appendage; LM  left main coronary artery; P  posterior;
PA  pulmonary artery; R  right; RCA  right coronary artery.
Abbreviations
and Acronyms
CHF  congestive heart
failure
CTA  computed
tomographic angiography
D  dimensional
NYHA  New York Heart
Association
TEE  transesophageal
echocardiography
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Percutaneous Closure of Paravalvular Leaks November 15, 2011:2210–7Patients were advised of the procedural risks and options
as well as the off-label use of all closure devices, and all
signed the informed consent. All procedures were per-
formed in the biplane structural heart catheterization labo-
ratory under general anesthesia. The study was approved by
Lenox Hill Hospital’s institutional review board.
Imaging. Pre-procedure, each patient underwent complete
diagnostic transthoracic echocardiography (TTE) and
Figure 2 3D CTA Guidance During Paravalvular Leak Closure P
A-P view: (A) 3-dimensional (3D) volume-rendered computed tomography angiograp
(B) “fluoro-like” view with the “target” remaining at the leak location; (C) live fluor
A  anterior; l  Left.
Patient Demographics and Medical HistoryTable 1 Patient Demographics and Medical History
Patients intended to treat 43
Male 29 (67.4)
Age 69.4 11.7
Time since last valve replacement, months 23.5 (2–322)
Patients with 1 prosthetic valve 28 (65)
Patients with 2 prosthetic valves 15 (35)
Number of thoracotomies per patient 1.8 1.2
Indication for procedure, hemolysis only 8 (14)
Indication for procedure, CHF only 9 (16)
Indication for procedure, hemolysis and CHF 40 (70)
Comorbidities
Pulmonary hypertension 14 (33)
Congestive heart failure 36 (84)
Systemic hypertension 26 (60)
Atrial fibrillation 10 (23)
Extensive coronary artery disease 18 (42)
Patients with coronary artery bypass grafts 14 (33)
Chronic renal insufficiency, creatinine 1.5 mg/dl 14 (33)
Permanent pacemaker 14 (33)
Values are n, n (%), mean  SD, or median (range).transesophageal echocardiography (TEE). Special attention
was paid to the morphology and the function of the native
and prosthetic valves. Initially, the size, location, and shape
of each paravalvular leak orifice were imaged, analyzed, and
measured. The location of the defects was determined by
our own modification (Fig. 1) of the clock-face system in
the “surgical view,” as previously described (12,13).
Electrocardiography-gated computed tomographic angiog-
raphy (CTA) with 3-dimensional (3D) and 4-dimensional
(4D) reconstruction using volume-rendering techniques
(TeraRecon, San Mateo, California) was also performed in
all but 1 patient to plan the best approach depending on
the position of the defect. The 64-slice Brilliance iCT
scanner (until 2008) and the 256-slice Brilliance iCT
scanner (Philips Healthcare, Cleveland, Ohio) were used
to perform the CTAs. The dehiscence length, width, and
area, as identified by echocardiography and CTA, per-
mitted the selection of the closure device best suited
to close the paravalvular leak while trying to avoid
embolization or interference with valve prosthesis
function.
When applicable, the degree of valvular regurgitation and
stenosis was evaluated by Doppler echocardiography using
the guidelines recommended by the American Society of
Echocardiography (14). Two-dimensional TEE (and real-
time 3D TEE when it became available in April 2008) was
performed throughout each procedure, using the IE-33
with the x7-2T 3D TEE probe (Philips, Andover, Massa-
chusetts). Three-dimensional modalities included live real
ure
A) for paravalvular leak localization and marking with the “target” cursor;
y. Lateral View: (D) 3D CTA; (E) “fluoro-like” view; (F) live fluoroscopy.roced
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November 15, 2011:2210–7 Percutaneous Closure of Paravalvular Leakstime, real-time 3D zoom, and full volume acquisition with
or without color Doppler.
During the procedure, 4D volume rendering of pre-
acquired CTA images were displayed in the catheteriza-
tion laboratory adjacent to the fluoroscopy image, using a
gray scale pre-set that simulates the live fluoroscopy
image (Fig. 2). The C-arm was rotated and angulated to
correspond to the angulations determined by the 3D
CTA to best profile the defect. The paravalvular leak was
“targeted” on the reconstructed image to facilitate cross-
ing with the guidewire.
Multiple imaging modalities were used during the pro-
cedures including 2D and 3D transthoracic echocardiogra-
phy, fluoroscopy, and CTA. Images were obtained and
recorded during each stage of the procedure. The operator
used the simultaneously displayed information to select the
approach and to guide the catheters and devices. That
included selection of the transseptal puncture site and the
demonstration of the wires and catheters across the para-
valvular leak, avoiding the valve orifice. Successful crossing
of the defect was confirmed by real-time 3D TEE (Fig. 3).
efore deployment and release of the occlusion device, the
alve was interrogated with Doppler echocardiography,
efore release, to ensure the absence of interference with
rosthetic valve function (resulting in regurgitation and/or
tenosis).
At the end of the procedure, careful echocardiographic
valuation was performed to review the presence of residual
eak, and to exclude complications such as pericardial effusion,
ntracardiac clot, and possible new intracardiac shunt.
aravalvular leak closure techniques. Aortic paravalvular
eaks were approached retrograde in all but 1 case, using
ifferent coronary catheters over hydrophilic guidewires as
reviously described (15). In 1 patient with both aortic and
itral paravalvular leaks, the aortic leak was closed antero-
Figure 3 Real-Time 3D TEE (Zoom Mode) Monitoring and Guida
The mitral valve is visualized from the left atrial perspective, and the image rotated to
noted in the 7 o’clock position of the mitral valve (black arrow). There is a new 8-mm
Occluder device is delivered to occlude the 1 o’clock dehiscence. Now, there are 2 ocgradely. All leaks were closed using Amplatzer-type oc-
cluder devices (AGA Medical, Plymouth, Minnesota).
Mitral paravalvular leaks closures were performed using 3
different approaches depending on the location of the leaks,
as previously described (15) The transseptal-antegrade tech-
nique was used mostly for leaks located between 6 o’clock
and 9 o’clock. The retrograde (retroaortic) technique was
often used for leaks located between 10 and 2 o’clock. The
transapical approach was used most often over the past 2
years for the majority of mitral paravalvular leaks, especially
if located between 10 and 6 o’clock. The transapical ap-
proach was accomplished by carefully planning the point of
entry into the left ventricle on the basis of a pre-acquired
CT angiogram. The transapical access was closed using
0.052-inch Gianturco Coils (Cook Medical, Bloomington,
Indiana) in 1 patient (16), a 6-mm Amplatzer Muscular
VSD Occluder (AGA Medical) in another patient, and a
6-mm to 4-mm Amplatzer Duct Occluder (AGA Medical)
in the remainder. Surgiflo (Ethicon, Somerville, New Jer-
sey) was also injected in the delivery sheath after release of
the closure device to fill the track to the skin.
Follow-up. All patients were evaluated post-procedure with
transthoracic echocardiography and 4D CTA. All patients
were either seen in our clinic or contacted by telephone for
ascertainment of clinical status (NYHA functional class),
requirements of blood transfusion, further surgical or catheter-
based intervention related to the paravalvular leaks, occurrence
of transient or permanent cerebrovascular accidents, myocar-
dial infarction, and bacterial endocarditis post-paravalvular leak
closure. For deceased patients, review of death certificates or
contact with referring physician and family was performed, to
ascertain the cause of death.
Data analysis. All demographic, valve-related, procedural
and outcome data, and clinical and anatomic data were
obtained from retrospective review of patient charts and pro-
During Paravalvular Leak Closing Procedure
e the “surgical view”. (A) A deployed Amplatzer Duct Occluder closure device is
alvular dehiscence at 1 o’clock (white arrow). (B) A new Amplatzer Muscular VSD
devices, the one at 1 o’clock and the other at 7 o’clock. 3D  3-dimensional.nce
provid
parav
cluding
2
p
p
C
d
e
e
o
d
i
a
p
f
p
2214 Ruiz et al. JACC Vol. 58, No. 21, 2011
Percutaneous Closure of Paravalvular Leaks November 15, 2011:2210–7cedural records. Statistical analyses were performed using the
SPSS statistical package (version 17.0, SPSS, Chicago, Illi-
nois). Continuous variables were reported as mean SD or as
a median and range when appropriate. Events are reported in
a nonhierarchical fashion. A Kaplan-Meier plot for survival
function was built using both phone visit data and data
obtained from chart review.
Results
There were 57 procedures performed in 43 patients with leaks
in biological valve prosthesis (65.3%) and mechanical valve
prosthesis (34.7%). Twelve patients had multiple procedures: 10
had 2 procedures and 2 patients had 3 procedures (Figure 4).
Using the clock-face diagram, the locations of the leaks treated
at the mitral valve were 18% located between 2 and 6 o’clock,
37% between 6 and 10 o’clock, and 45% between 10 and 2
o’clock; at the aortic valve, there were 36% between 11 and 3
o’clock (left coronary cusp), 18% between 3 and 7 o’clock (right
coronary cusp), and 46% between 7 and 11 o’clock (noncoro-
nary cusp).
Technical success. Successful deployment was achieved in
86% (42 of 49) of leaks and 86% (37 of 43) of patients.
Worsening or development of new hemolysis, determined by
increase in lactate dehydrogenase level, was documented in 13
of 37 patients in whom the procedure was successful.
There were 12 procedural failures to deploy the occlusive
devices, 8 due to inability to cross the defect with the
delivery system, 3 due to device interference with the
Figure 4 Study Group Profile
Forty-four patients were referred to our structural heart disease center. One patien
leak closure procedures. Thirty-one patients underwent 1 procedure, 10 patients u
leaks closures were attempted: 38 mitral paravalvular leaks and 11 aortic paraval
2 mitral paravalvular leaks.mechanical function of the valve prosthesis, and 1 due to
wire entrapment during the attempt to cross the aortic
paravalvular leak.
As shown in Table 2, there were 36 mitral paravalvular
leaks treated in 32 patients, 9 aortic paravalvular leaks
treated in 8 patients, and 2 patients with paravalvular leaks
treated in both valves. Four patients had 2 different para-
valvular leaks closed during the same procedure: 3 had 2
mitral paravalvular leaks closed and the other had 1 para-
valvular leak closed in both the aortic and mitral valves. The
Amplatzer Duct Occluder was used in 68.9% of the proce-
dures, the Amplatzer Muscular VSD Occluder in 18.7%,
the Amplatzer Vascular Plug II in 8.3%, and the Amplatzer
Septal Occluder in 4.1%. Average fluoroscopy time was 39.0
8.8 min for all procedures, 42.6  29.9 min for mitral
aravalvular leaks procedures and 29.9 24.5 min for aortic
aravalvular leaks procedures.
omplications. Six patients experienced complications
uring the paravalvular leak closure. Two patients had an acute
mbolization of an occlusion device. The first patient had
mbolization of the closure device during the attempted closure
f a crescent-shaped mitral paravalvular leak with simultaneous
eployment of 2 Amplatzer Duct Occluder devices. The device
nitially embolized to the left atrium, then to the left ventricle,
nd subsequently to the aortic bifurcation. The device was
ercutaneously retrieved, and the paravalvular leak was success-
ully closed by utilizing a larger second device during the same
rocedure. A second patient had an embolization of the
excluded, and all remaining 43 patients underwent 57 percutaneous paravalvular
ent 2 procedures, and 2 patients underwent 3 procedures. In all, 49 paravalvular
eaks. Twenty-six patients had 1 mitral paravalvular leak, and 6 patients hadt was
nderw
vular l
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November 15, 2011:2210–7 Percutaneous Closure of Paravalvular LeaksAmplatzer Duct Occluder device, placed in an aortic paraval-
vular leak, in the left ventricle detected by echocardiography a
few hours after the procedure. A second larger device was then
placed during the same hospitalization to successfully close the
leak. The embolized device was firmly imbedded behind the
papillary muscle and remains in a stable position by 2D
echocardiography and CTA 6 months post-procedure. The
third complication occurred in a patient who had an entrapped
wire during the procedure that required surgical removal (17).
A fourth patient experienced a non–flow-limiting external iliac
artery dissection requiring no intervention. Two additional
patients had minor cardiac perforations that occurred during
the transseptal procedures. Both were associated with pericar-
dial effusions that required no intervention.
There was 1 procedure-related death in a patient with
suprasystemic pulmonary hypertension who experienced
pulseless electrical activity (electromechanical dissociation)
after a successful PVL closure. The patient had no tampon-
Procedural OutcomesTable 2 Procedural Outcomes
Total number of procedures 57
Number of patients with mitral PVL 32 (74)
Number of patients with aortic PVL 9 (21)
Number of patients with aortic PVL and mitral PVL 2 (5)
Mitral PVL leak locations*
2–6 7 (18)
6–10 14 (37)
10–2 17 (45)
Aortic PVL leak locations*
11–3 4 (36)
3–7 2 (18)
7–11 5 (46)
Mitral PVLs intended to treat 38
Mitral PVLs successfully treated 34 (89)
Mitral PVLs requiring a second procedure to close 5 (14)
Mitral PVLs in biological valves 26 (68)
Mitral PVLs in mechanical valves 12 (32)
Aortic PVLs intended to treat 11
Aortic PVLs successfully treated 8 (73)
Aortic PVLs requiring a second procedure to close 3 (27)
Aortic PVLs in biological valves 6 (55)
Aortic PVLs in mechanical valves 5 (45)
Procedural failures
Valve interference, device withdrawal 3 (5)
Failure to cross with delivery system 8 (14)
Wire entrapment, conversion to surgery 1 (2)
Fluoroscopy time, min 39.0 28.8
Mitral PVL 42.6 29.9
Aortic PVL 29.9 24.5
Complications
Acute embolization 2 (4)
Wire entrapped, conversion to surgery 1 (2)
Cardiac perforation 2 (4)
Iliac artery dissection 1 (2)
Procedure-related death 1 (2)
Values are n, n (%), or mean  SD. *See Figure 1.
PVL  paravalvular leak.ade, as confirmed by echocardiography and an emergencythoracotomy. There was 1 non–procedure-related death due
to an intracerebral bleed 5 days after the procedure.
Clinical success. Clinical success was achieved in 89% (33
of 37 patients) with successful closure of the paravalvular
leak. Eighteen patients improved by 1 NYHA functional
class, 8 patients improved by 2 functional classes, and 2
patients improved by 3 functional classes (Fig. 5). Seven
patients did not improve in NYHA functional class, but 5 of
them had resolution of hemolysis, and therefore were
considered a clinical success. The percentage of patients
requiring blood transfusions or erythropoietin injections
decreased from 56% pre-procedure to 5% at follow-up.
Follow-up. On the basis of the follow-up of 37 patients in
whom the procedure was successful, 28 have had an im-
provement in NYHA functional class by at least 1 class, and
33 patients have not required any blood transfusions or
erythropoietin injections after the procedure.
The survival rates for patients at 6, 12, and 18 months
after undergoing paravalvular leak closures are 91.9%,
89.2%, and 86.5%, respectively (Fig. 6). These rates include
2 non–cardiac-related deaths that occurred at 11 months
(head trauma) and 13 months (bronchopneumonia and
sepsis) post-procedure, with both patients exhibiting clinical
improvement. A third patient, with persistent residual leak,
underwent surgical repair in spite of clinical improvement
but died during surgery. Freedom from cardiac-related
death after 6, 12, and 18 months was 91.9%.
Discussion
This analysis represents the largest series of percutaneous
paravalvular leak closures yet reported. In this study, pa-
tients demonstrated significant and marked improvement in
Figure 5 NYHA-Functional Class in 35 Patients Before
and After Technically Successful Procedure
Figure does not include 2 patients who underwent technically successful proce-
dure but who died within 30 days of the procedure. NYHA-FC  New York Heart
Association functional class.
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Percutaneous Closure of Paravalvular Leaks November 15, 2011:2210–7both CHF symptoms and the need for blood transfusions
for ongoing hemolysis.
Hein et al. (18) observed that 33% of patients requiring
transfusions had worsening hemolysis after the procedure, and
there was newly developed hemolysis in 10% of all patients.
This series had similar results immediately after the procedure.
It has been determined best to wait 6 months, while minimiz-
ing blood transfusions using erythropoietin injections as
needed, to ascertain whether severe hemolysis was ongoing and
a second closing procedure was indeed needed (i.e., second
percutaneous procedure or surgery).
The 30-day all cause mortality rate of 5.4% appears to be
lower than that of 1 large surgical series (12%) (3). Percutane-
us paravalvular leaks closure may become increasingly favor-
ble after 1 reoperation as surgical mortality rates as high as
2% have been reported (3,5). The cardiac-related mortality
ate at 6 months of 8.1% also appears to be considerably lower
han that of conservative medical management (26%) (3).
Figure 6 Kaplan-Meier Plot of Survival Function
for 42 Months Post-Procedure
Red line  total survival rate; blue line  freedom from cardiac-related death.
Current PublicationsTable 3 Current Publications
First Author (Ref. #) Year Type (n) Patients (n)
Hourihan et al. (10) 1992 A 3
Pate et al. (20) 2006 M (9) 10
A (1)
Hein et al. (18) 2006 M (13) 21
A (8)
Shapira et al. (21) 2007 M (9) 11
A (2)
Sorajja et al. (22) 2007 M (14) 16
A (2)
Cortes et al. (19) 2008 M 27
Garcı´a-Borbolla Ferna´ndez et al. (11) 2009 M 8
Nietlispach et al. (25) 2010 A (1) 5
M (4)A  aortic paravalvular leak; M  mitral paravalvular leak; n/a  not available.As previously reported (10,11,18–22) (Table 3), the
ercutaneous paravalvular leak closure outcomes with the
urrent available technology still leave a lot to be desired,
wing to several issues. 1) There are no devices that are
pecifically designed to treat this problem; the devices
hat are currently employed are being utilized “off-label.”
) Paravalvular leaks may be difficult to cross because of
heir position and/or because of the anatomic configura-
ion of the defects that may be serpiginous and/or rigid
ue to annular calcification or to the valve ring per se. At
imes, the defect can be crossed with a guidewire, but
rossing with an available delivery sheath or catheter may
e impossible (8 of 12 of our failures). 3) The defect may
e crossed and closed but the closure device may interfere
ith the function of the prosthetic valve, prohibiting
elease of the device (3 of 12 of our failures). However,
ith this limited number of patients, we cannot deter-
ine if the type of prosthesis and the type of closure
evices used can influence the outcome. The develop-
ent of newer low profile and largely adaptive devices
hat can conform to the variety of shapes of these defects
nd are specifically designed for this application will
ndoubtedly improve the current results.
In the current study, procedural and clinical success as well
s complications rate appear acceptable. This series incorpo-
ates the use of multiple imaging modalities to facilitate the
lanning and performance of the procedure. The relatively
igh rate of procedural success may have been related to the
lose collaboration and communication between the 4D CTA
econstruction specialist, the transesophageal echocardiography
pecialist, and the interventional cardiologist, both before the
rocedure to plan the approach and during the procedure to
onfirm the course of wires and catheters in the 3D space
ithin the heart. Targeting the paravalvular leak on the 4D
TA reconstructed image adjacent to the fluoroscopic image
reatly enhanced the ability to cross the defect in an expedi-
ious fashion. These procedures can be challenging and tech-
ically demanding, but are clearly facilitated by a “team
ks (n)
Technical
Success
Clinical
Success
Repeat
Procedures
Mean Fluoroscopy
Time (min)
3 3 (100%) 2 (67%) 1 (33%) n/a
10 7 (70%) 4 (57%) 4 (40%) 62
26 24 (92%) 14 (67%) 9 (43%) 31
13 11 (85%) 6 (54%) 1 (8%) 60
19 17 (89%) 12 (75%) 0 (0%) 55
27 17 (63%) 10 (59%) 0 (0%) n/a
8 5 (63%) 4 (80%) 0 (0%) n/a
5 5 (100%) 5 (100%) 0 (0%) 15Lea
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
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denced by the relatively long fluoroscopy times of 42.6 min for
mitral and 29.9 min for aortic paravalvular leaks closures.
Continued careful long-term follow-up by the clinical car-
diologist is warranted in view of the possibility of additional
paravalvular leaks developing as well as continued CHF and/or
hemolysis requiring transfusion resulting from incomplete
closure. Late embolization of the closure device has also been
reported (23,24), although this event was not observed in this
series. In some cases, hemolysis may temporarily worsen before
improving because of increased shear stress through the device
before it has a chance to endothelialize.
Conclusions
Percutaneous closure of symptomatic paravalvular leaks
requires multiple imaging modalities and the ability to
visualize the 3D relationships of intracardiac structures. A
collaborative effort with a skilled interventional team con-
sisting of a structural heart disease interventionalist, an
echocardiographer skilled in 3D echo reconstruction, and a
CT specialist skilled in 4D reconstruction can result in
successful outcomes with improvements in functional class
and hemolysis, and with apparently lower morbidity and
mortality rates in comparison to surgical series.
Reprint requests and correspondence: Dr. Carlos E. Ruiz, Lenox
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